Source comparison
CJC-1295 No DAC Muscle Growth Protocol: Dosing Comparison
Standard 3x Daily 100mcg 3x per day (morning, post-workout, pre-sleep) Aligns with waking, exercise-induced, and nocturnal pulses 8–12 weeks Muscle hypertrophy, IGF-1 elevation, recovery optimization Gold standard for muscle growth research. Maximizes pulsatil
This comparison does not assign a generated winner or score.
- Standard 3x Daily
- 100mcg
- 3x per day (morning, post-workout, pre-sleep)
- Aligns with waking, exercise-induced, and nocturnal pulses
- 8–12 weeks
- Muscle hypertrophy, IGF-1 elevation, recovery optimization
- Gold standard for muscle growth research. Maximizes pulsatile GH amplification across all three physiological peaks
- 2x Daily (Simplified)
- 2x per day (morning, pre-sleep)
- Captures waking and nocturnal pulses only
- Muscle retention during caloric deficit, anti-catabolic research
- Effective for maintenance and retention. Misses post-exercise pulse, which is the most anabolic window for IGF-1 synthesis
- High-Dose Single Daily
- 200mcg
- 1x per day (pre-sleep)
- Nocturnal pulse only
- 4–8 weeks
- Sleep quality and recovery research, not optimized for muscle growth
- Least effective for muscle hypertrophy. Receptor saturation limits benefit, and single-pulse amplification cannot match three-pulse protocol outcomes
- Cycling Protocol
- 3x per day, 5 days on / 2 days off
- Same as standard, with weekly breaks
- 12–16 weeks
- Long-term protocols exploring receptor sensitivity maintenance
- Emerging approach. Data suggests cycling may prevent desensitization, but current evidence does not show superiority over continuous dosing
- Effective CJC-1295 No DAC protocols for muscle growth require three daily injections timed to physiological GH peaks. Two-dose protocols work for maintenance but sacrifice the post-workout pulse, which is the most anabolic window. Single daily dosing does not produce muscle growth outcomes comparable to multi-dose protocols. The half-life is too short to sustain elevated IGF-1 across 24 hours.